跳至主要内容
临床试验/NCT04019379
NCT04019379进行中(未招募)不适用

Calcium and Phosphorus Whole-Body Balance and Kinetics in Patients With Moderate Chronic Kidney Disease

University of Minnesota2 个研究点 分布在 1 个国家目标入组 3 人开始时间: 2020年8月31日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
3
试验地点
2
主要终点
Fractional Calcium Absorption

研究概览

简要总结

This pilot study aims to develop a method for simultaneous whole-body calcium and phosphorus balance and full kinetic modeling of both ions in patients with chronic kidney disease.

详细描述

The goal of this project is to produce preliminary data on the effects of the commonly prescribed dietary phosphorus restriction on whole-body Calcium (Ca) and Phosphorus (P) balance and kinetics patients with CKD, to support a larger future clinical study. The specific aims are to determine intestinal Ca and P fractional absorption and 2) Ca and P balance and full kinetics, effect sizes variance estimates in patients with CKD on a low Ca diet with high P diet versus dietary P restriction. The hypothesis is that a high P diet, in the context of a typical low Ca diet, leads to P retention negative Ca balance, and that dietary P restriction modestly reduces P retention but does not negative Ca balance.

The study design is a randomized 2-period cross-over study. All outpatient and inpatient visits place at the Indiana CTSI Clinical Research Center located in IU Health University Hospital in Indianapolis, IN. Subjects will be randomly assigned to controlled diets of either low Ca/high P (LCa/HP) or low (LCa/LP) for a 1-week, outpatient diet equilibration period, followed by 1-week inpatient full balance that includes a 48-hour Ca and P absorption testing protocol. After a 1-3 week washout subjects will crossover to the other diet regimen

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
30 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men or women, ages 30-75 years old, any race or ethnicity
  • Moderate chronic kidney disease
  • Female subjects must be postmenopausal (>12 months since last menstrual period), surgically sterile, or confirmed not pregnant by pregnancy test
  • Must be on stable doses of medications (except those noted in exclusion criteria) for at least 4 weeks prior to the study
  • Willing to discontinue nutritional supplements (e.g. vitamin D, calcium, multivitamin/minerals, or others) upon enrollment until completion of the study
  • Adequate vitamin D status defined as serum 25D > 20 ng/mL

排除标准

  • Plans to initiate dialysis within 6 months
  • Hypercalcemia defined as serum calcium >10.5 mg/dL within past 3 months
  • Hyperkalemia defined as serum potassium >5.5 mg/dL within past 3 months
  • Hyperphosphatemia defined as serum phosphate >5.5 mg/dL within past 3 months
  • Intestinal disease that alters absorption or normal intestinal function including celiac disease, small bowel resection, or bariatric surgery
  • Serious, uncontrolled underlying systemic disease including diabetes, lupus, hypertension
  • Pregnant or breastfeeding
  • Prescribed a phosphate binder medication, calcitriol, vitamin D analogs, calcimimetics, parathyroid hormone analogues, and other medications that may alter Ca and P metabolism within past 30 days

结局指标

主要结局

Fractional Calcium Absorption

时间窗: 48 hours

Determined by kinetic modeling of serum and urine Ca-44 isotope after oral and IV isotope administrations

Fractional Phosphorus Absorption

时间窗: 48 hours

Determined by kinetic modeling of serum and urine P-33 isotope after oral and IV isotope administrations

Calcium Balance

时间窗: 1 week

Determined by analysis of calcium content in complete 24-hour urine and stool collections, subtracted from the diet calcium content consumed. Values can be negative, zero, or positive.

Phosphorus Balance

时间窗: 1 weeks

Determined by analysis of phosphorus content in complete 24-hour urine and stool collections, subtracted from the diet phosphorus content consumed. Values can be negative, zero, or positive.

次要结局

  • Serum Intact Fibroblast Growth Factor 23 (iFGF23)(Day 1-8)
  • Serum Intact Parathyroid Hormone (iPTH)(Day 1-8)
  • Serum 1,25-dihydroxyvitamin D (1,25D)(Day 1)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验